Blood sample collection: Blood samples collection: at Day (D)-6 and D0 before CAR-T cells injection, post injection at Day (D)3, D5,D7, D9, D11, D14, D18, D 21, Month 2 and Month 12 post injection.
Study summary
In the frame of Si-CART study, blood will be collected from patients treated with CAR-T cells: before (at Day (D)-6 and D0 before cells injection), post infusion at D3, D5,D7, D9, D11, D14, D18, D 21, Month (M) 2 and M12 post injection.
A cerebrospinal fluid sample will also be collected if a Cerebrospinal Fluid Analysis Lumbar puncture is performed
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years
* Planned injection of CAR-T cells within the scope of marketing authorization
* Signed informed consent
* French social security affiliation
Exclusion Criteria:
* Pregnant women, or women of childbearing potential (without medically acceptable contraception) or breastfeeding women.
* Patient in emergency situation, adult under legal protection (patient placed under tutorship, curatorship, or judicial protection) or unable to give his consent
* Impossibility to comply with trial medical follow-up for geographic, social or psychological reasons
Primary outcome measure(s)
Correlation between serum markers and adverse events at 1 year of the CAR-T cells infusion — 1 year after T cells infusion Serum concentration of cytokines in relation to adverse events
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
